Piyasa açık· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs. The agreement extends Ligand’s royalty-focused approach, giving the business potential future royalty rights on AvenCell’s existing CAR-T pipeline and any later programs that emerge from the partnership. Recent trading has been strong for...
Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. With a Discounted Cash Flow (DCF) view available, the focus naturally turns to how the current price lines up with the cash flows investors expect the company to produce over time. Over the past 3 years, Ligand Pharmaceuticals has returned about 430.8%, which puts a lot of weight on whether the cash flow...
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.